Conduit Pharmaceuticals Statistics
Total Valuation
CDT has a market cap or net worth of $2.19 million. The enterprise value is $2.93 million.
Important Dates
The next estimated earnings date is Monday, August 11, 2025, before market open.
| Earnings Date | Aug 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CDT has 952,230 shares outstanding. The number of shares has increased by 138.76% in one year.
| Current Share Class | 952,230 |
| Shares Outstanding | 952,230 |
| Shares Change (YoY) | +138.76% |
| Shares Change (QoQ) | +247.24% |
| Owned by Insiders (%) | 0.98% |
| Owned by Institutions (%) | 6.03% |
| Float | 814,384 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.54 |
| P/TBV Ratio | 0.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.31, with a Debt / Equity ratio of 1.07.
| Current Ratio | 1.31 |
| Quick Ratio | 0.58 |
| Debt / Equity | 1.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.54 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -168.26% |
| Return on Invested Capital (ROIC) | -549.10% |
| Return on Capital Employed (ROCE) | -594.05% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.23M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.91% in the last 52 weeks. The beta is 1.99, so CDT's price volatility has been higher than the market average.
| Beta (5Y) | 1.99 |
| 52-Week Price Change | -99.91% |
| 50-Day Moving Average | 6.43 |
| 200-Day Moving Average | 82.40 |
| Relative Strength Index (RSI) | 24.64 |
| Average Volume (20 Days) | 540,812 |
Short Selling Information
The latest short interest is 55,709, so 5.85% of the outstanding shares have been sold short.
| Short Interest | 55,709 |
| Short Previous Month | 765,323 |
| Short % of Shares Out | 5.85% |
| Short % of Float | 6.84% |
| Short Ratio (days to cover) | 0.64 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -16.47M |
| Pretax Income | n/a |
| Net Income | -19.40M |
| EBITDA | n/a |
| EBIT | -16.47M |
| Earnings Per Share (EPS) | -$175.91 |
Full Income StatementBalance Sheet
The company has $2.13 million in cash and $2.87 million in debt, giving a net cash position of -$737,000 or -$0.77 per share.
| Cash & Cash Equivalents | 2.13M |
| Total Debt | 2.87M |
| Net Cash | -737,000 |
| Net Cash Per Share | -$0.77 |
| Equity (Book Value) | 2.69M |
| Book Value Per Share | 4.24 |
| Working Capital | 1.40M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$11.65 million and capital expenditures -$55,000, giving a free cash flow of -$11.71 million.
| Operating Cash Flow | -11.65M |
| Capital Expenditures | -55,000 |
| Free Cash Flow | -11.71M |
| FCF Per Share | -$12.30 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |